BioSpace News Archive

Pfizer is lining up a potential New Drug Application for an ulcerative colitis treatment for patients who are not seeing an improvement in their condition from currently available options.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

The 4D pharma has shared positive interim results from its Phase I/II study of a combination therapeutic for the treatment of renal cell carcinoma (RCC).

BioAge Labs presented new data demonstrating how its drug candidate BGE-175 is uniquely poised to tackle age-related immune system decline that leads to disease progression.

CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.

Waterdrop Inc. today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2021.

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules from the biosphere, announced the completion of a $175 million Series C financing.

Pfizer Inc. announced positive topline results from a Phase 3 study of etrasimod, an investigational, oral, once-a-day, selective sphingosine 1-phosphate receptor modulator in development for the treatment of moderately to severely active ulcerative colitis.

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest.

Indaptus Therapeutics, Inc. will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made available Monday, March 28, 2022 at 9:00 a.m. ET.